Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry In Focus: US Home Health Care Revenues Set to Exceed $5 Billion by 2012

Executive Summary

The US home health care market, valued at nearly $4.5 billion in 2009, is set to experience steady growth in the years ahead, driven by a burgeoning aging population, a critical need for cost-effective solutions for patients suffering from long-term chronic conditions, and the increasing use of technology to meet the needs of those receiving home-based medical care. According to Medtech Insight's recent report "US Markets for Home Health Care Products," sales revenues for the major home health care product segments are expected to reach $5.2 billion by 2012.

You may also be interested in...



Homing In On the Wireless Monitoring Opportunity

The struggling US economy is forcing health care providers and government agencies to step up efforts to find cheaper and more efficient ways of delivering care, and home health offers a number of expanding opportunities. Advances in communication technology, specifically the ability to monitor remotely through a variety of wireless devices, are driving the market.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel